Activation of the EGF receptor by ligand binding and oncogenic mutations: The “rotation model”

Cells

Volumn 6, Issue 2, 2017, Pages

  Purba, Endang R ^a   Saita, Ei Ichiro ^a   Maruyama, Ichiro N ^a  

^a OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY GRADUATE UNIVERSITY   (Japan)

Author keywords

Cancer; Cell surface receptor; EGFR; Molecular mechanism; Phosphorylation; Receptor tyrosine kinase; Transmembrane signal transduction

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

AUTOPHOSPHORYLATION; CELL DIFFERENTIATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; ENDOCYTOSIS; FLUORESCENCE CORRELATION SPECTROSCOPY; FLUORESCENCE MICROSCOPY; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE AMPLIFICATION; GENE MUTATION; HUMAN; LIGAND BINDING; OLIGOMERIZATION; PHOSPHORYLATION; REVIEW; SEQUENCE ANALYSIS; STIMULATION;

EID: 85038258025     PISSN: None     EISSN: 20734409     Source Type: Journal    
DOI: 10.3390/cells6020013     Document Type: Review

References (157)

1. Olayioye, M.A.; Neve, R.M.; Lane, H.A.; Hynes, N.E. The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J. 2000, 19, 3159-3167.
2. Miettinen, P.J.; Berger, J.E.; Meneses, J.; Phung, Y.; Pedersen, R.A.; Werb, Z.; Derynck, R. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 1995, 376, 337-341.
3. Sibilia, M.; Wagner, E.F. Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 1995, 269, 234-238.
4. Threadgill, D.W.; Dlugosz, A.A.; Hansen, L.A.; Tennenbaum, T.; Lichti, U.; Yee, D.; LaMantia, C.; Mourton, T.; Herrup, K.; Harris, R.C.; et al. Targeted disruption of mouse EGF receptor: Effect of genetic background on mutant phenotype. Science 1995, 269, 230-234.
5. Hynes, N.E.; MacDonald, G. ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell Biol. 2009, 21, 177-184.
6. Hynes, N.E.; Lane, H.A. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5, 341-354.
7. Harris, R.C.; Chung, E.; Coffey, R.J. EGF receptor ligands. Exp. Cell Res. 2003, 284, 2-13.
8. Maruyama, I.N. Mechanisms of activation of receptor tyrosine kinases: Monomers or dimers. Cells 2014, 3, 304-330.
9. Ullrich, A.; Coussens, L.; Hayflick, J.S.; Dull, T.J.; Gray, A.; Tam, A.W.; Lee, J.; Yarden, Y.; Libermann, T.A.; Schlessinger, J.; et al., Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984, 309, 418-425.
10. Jones, S.; Rappoport, J.Z. Interdependent epidermal growth factor receptor signalling and trafficking. Int. J. Biochem. Cell Biol. 2014, 51, 23-28.
11. Lemmon, M.A. Ligand-induced ErbB receptor dimerization. Exp. Cell Res. 2009, 315, 638-648.
12. Jorissen, R.N.; Walker, F.; Pouliot, N.; Garrett, T.P.; Ward, C.W.; Burgess, A.W. Epidermal growth factor receptor: Mechanisms of activation and signaling. Exp. Cell Res. 2003, 284, 31-53.
13. Burgess, A.W.; Cho, H.S.; Eigenbrot, C.; Ferguson, K.M.; Garrett, T.P.; Leahy, D.J.; Lemmon, M.A.; Sliwkowski, M.X.; Ward, C.W.; Yokoyama, S. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell 2003, 12, 541-552.
14. Ogiso, H.; Ishitani, R.; Nureki, O.; Fukai, S.; Yamanaka, M.; Kim, J.H.; Saito, K.; Sakamoto, A.; Inoue, M.; Shirouzu, M.; et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002, 110, 775-787.
15. Garrett, T.P.; McKern, N.M.; Lou, M.; Elleman, T.C.; Adams, T.E.; Lovrecz, G.O.; Zhu, H.J.; Walker, F.; Frenkel, M.J.; Hoyne, P.A.; et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 2002, 110, 763-773.
16. Ward, C.W.; Garrett, T.P.J. The relationship between the L1 and L2 domains of the insulin and epidermal growth factor receptors and leucine-rich repeat modules. BMC Bioinform. 2001, 2, 4.
17. Ward, C.W.; Garrett, T.P.J.; McKern, N.M.; Lou, M.; Cosgrove, L.J.; Sparrow, L.G.; Frenkel, M.J.; Hoyne, P.A.; Elleman, T.C.; Adams, T.E.; et al. The three dimensional structure of the type I insulin-like growth factor receptor. Mol. Pathol. 2001, 54, 125-132.
18. Bradshaw, R.A.; Chalkley, R.J.; Biarc, J.; Burlingame, A.L. Receptor tyrosine kinase signaling mechanisms:Devolving TrkA responses with phosphoproteomics. Adv. Biol. Regul. 2013, 53, 87-96.
19. Tong, J.; Taylor, P.; Jovceva, E.; St-Germain, J.R.; Jin, L.L.; Nikolic, A.; Gu, X.; Li, Z.H.; Trudel, S.; Moran, M.F. Tandem immunoprecipitation of phosphotyrosine-mass spectrometry (TIPY-MS) indicates C19ORF19 becomes tyrosine-phosphorylated and associated with activated epidermal growth factor receptor. J. Proteome Res. 2008, 7, 1067-1077.
20. Wilson, K.J.; Gilmore, J.L.; Foley, J.; Lemmon, M.A.; Riese, D.J., 2nd. Functional selectivity of EGF family peptide growth factors: Implications for cancer. Pharmacol. Ther. 2009, 122, 1-8.
21. Pawson, T. Regulation and targets of receptor tyrosine kinases. Eur. J. Cancer 2002, 38, S3-S10.
22. Miloso, M.; Mazzotti, M.; Vass, W.C.; Beguinot, L. SHC and GRB-2 are constitutively activated by an epidermal growth factor receptor with a point mutation in the transmembrane domain. J. Biol. Chem. 1995, 270, 19557-19562.
23. Lemmon, M.A.; Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 2010, 141, 1117-1134.
24. Mendoza, M.C.; Er, E.E.; Blenis, J. The Ras-ERK and PI3K-mTOR pathways: Cross-talk and compensation. Trends Biochem. Sci. 2011, 36, 320-328.
25. Kovacs, E.; Zorn, J.A.; Huang, Y.; Barros, T.; Kuriyan, J. A structural perspective on the regulation of the epidermal growth factor receptor. Annu. Rev. Biochem. 2015, 84, 739-764.
26. Lemmon, M.A.; Schlessinger, J.; Ferguson, K.M. The EGFR family: Not so prototypical receptor tyrosine kinases. Cold Spring Harb. Perspect. Biol. 2014, 6, a020768.
27. Roskoski, R., Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol. Res. 2014, 79, 34-74.
28. Bessman, N.J.; Freed, D.M.; Lemmon, M.A. Putting together structures of epidermal growth factor receptors. Curr. Opin. Struct. Biol. 2014, 29, 95-101.
29. Bae, J.H.; Schlessinger, J. Asymmetric tyrosine kinase arrangements in activation or autophosphorylation of receptor tyrosine kinases. Mol. Cells 2010, 29, 443-448.
30. Yarden, Y.; Schlessinger, J. Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. Biochemistry 1987, 26, 1443-1451.
31. Boni-Schnetzler, M.; Pilch, P.F. Mechanism of epidermal growth factor receptor autophosphorylation and high-affinity binding. Proc. Natl. Acad. Sci. USA 1987, 84, 7832-7836.
32. Cochet, C.; Kashles, O.; Chambaz, E.M.; Borrello, I.; King, C.R.; Schlessinger, J. Demonstration of epidermal growth factor-induced receptor dimerization in living cells using a chemical covalent cross-linking agent. J. Biol. Chem. 1988, 263, 3290-3295.
33. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103, 211-225.
34. Weiss, F.U.; Daub, H.; Ullrich, A. Novel mechanisms of RTK signal generation. Curr. Opin. Genet. Dev. 1997, 7, 80-86.
35. Ullrich, A.; Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990, 61, 203-212.
36. Maruyama, I.N. Activation of transmembrane cell-surface receptors via a common mechanism? The “rotation model.” Bioessays 2015, 37, 959-967.
37. Moriki, T.; Maruyama, H.; Maruyama, I.N. Activation of preformed EGF receptor dimers by ligandinduced rotation of the transmembrane domain. J. Mol. Biol. 2001, 311, 1011-1026.
38. Yu, X.; Sharma, K.D.; Takahashi, T.; Iwamoto, R.; Mekada, E. Ligand-independent dimer formation of epidermal growth factor receptor (EGFR) is a step separable from ligand-induced EGFR signaling. Mol. Biol. Cell 2002, 13, 2547-2557.
39. Liu, P.; Sudhaharan, T.; Koh, R.M.; Hwang, L.C.; Ahmed, S.; Maruyama, I.N.; Wohland, T. Investigation of the dimerization of proteins from the epidermal growth factor receptor family by single wavelength fluorescence cross-correlation spectroscopy. Biophys. J. 2007, 93, 684-698.
40. Clayton, A.H.; Walker, F.; Orchard, S.G.; Henderson, C.; Fuchs, D.; Rothacker, J.; Nice, E.C.; Burgess, A.W. Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-A multidimensional microscopy analysis. J. Biol. Chem. 2005, 280, 30392-30399.
41. Martin-Fernandez, M.; Clarke, D.T.; Tobin, M.J.; Jones, S.V.; Jones, G.R. Preformed oligomeric epidermal growth factor receptors undergo an ectodomain structure change during signaling. Biophys. J. 2002, 82, 2415-2427.
42. Saffarian, S.; Li, Y.; Elson, E.L.; Pike, L.J. Oligomerization of the EGF receptor investigated by live cell fluorescence intensity distribution analysis. Biophys. J. 2007, 93, 1021-1031.
43. Yavas, S.; Machan, R.; Wohland, T. The epidermal growth factor receptor forms location-dependent complexes in resting cells. Biophys. J. 2016, 111, 2241-2254.
44. Ma, X.; Ahmed, S.; Wohland, T. EGFR activation monitored by SW-FCCS in live cells. Front. Biosci. (Elite Ed.) 2011, 3, 22-32.
45. Hofman, E.G.; Bader, A.N.; Voortman, J.; van den Heuvel, D.J.; Sigismund, S.; Verkleij, A.J.; Gerritsen, H.C.; van Bergen en Henegouwen, P.M. Ligand-induced EGF receptor oligomerization is kinase-dependent and enhances internalization. J. Biol. Chem. 2010, 285, 39481-39489.
46. Bader, A.N.; Hofman, E.G.; Voortman, J.; En Henegouwen, P.M.; Gerritsen, H.C. Homo-FRET imaging enables quantification of protein cluster sizes with subcellular resolution. Biophys. J. 2009, 97, 2613-2622.
47. Teramura, Y.; Ichinose, J.; Takagi, H.; Nishida, K.; Yanagida, T.; Sako, Y. Single-molecule analysis of epidermal growth factor binding on the surface of living cells. EMBO J. 2006, 25, 4215-4222.
48. Tao, R.H.; Maruyama, I.N. All EGF (ErbB) receptors have performed homo- and heterodimeric structures in living cells. J. Cell Sci. 2008, 121, 3207-3217.
49. Yang, K.S.; Ilagan, M.X.; Piwnica-Worms, D.; Pike, L.J. Luciferase fragment complementation imaging of conformational changes in the epidermal growth factor receptor. J. Biol. Chem. 2009, 284, 7474-7482.
50. Macdonald-Obermann, J.L.; Piwnica-Worms, D.; Pike, L.J. Mechanics of EGF receptor/ErbB2 kinase activation revealed by luciferase fragment complementation imaging. Proc. Natl. Acad. Sci. USA 2012, 109, 137-142.
51. Macdonald-Obermann, J.L.; Adak, S.; Landgraf, R.; Piwnica-Worms, D.; Pike, L.J. Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging. J. Biol. Chem. 2013, 288, 30773-30784.
52. Knebel, A.; Rahmsdorf, H.J.; Ullrich, A.; Herrlich, P. Dephosphorylation of receptor tyrosine kinases as target of regulation by radiation, oxidants or alkylating agents. EMBO J. 1996, 15, 5314-5325.
53. Yamashita, H.; Yano, Y.; Kawano, K.; Matsuzaki, K. Oligomerization-function relationship of EGFR on living cells detected by the coiled-coil labeling and FRET microscopy. Biochim. Biophys. Acta 2015, 1848, 1359-1366.
54. Valley, C.C.; Arndt-Jovin, D.J.; Karedla, N.; Steinkamp, M.P.; Chizhik, A.I.; Hlavacek, W.S.; Wilson, B.S.; Lidke, K.A.; Lidke, D.S. Enhanced dimerization drives ligand-independent activity of mutant epidermal growth factor receptor in lung cancer. Mol. Biol. Cell 2015, 26, 4087-4099.
55. Chung, I.; Akita, R.; Vandlen, R.; Toomre, D.; Schlessinger, J.; Mellman, I. Spatial control of EGF receptor activation by reversible dimerization on living cells. Nature 2010, 464, 783-787.
56. Huang, Y.; Bharill, S.; Karandur, D.; Peterson, S.M.; Marita, M.; Shi, X.; Kaliszewski, M.J.; Smith, A.W.; Isacoff, E.Y.; Kuriyan, J. Molecular basis for multimerization in the activation of the epidermal growth factor receptor. eLife 2016, 5, e14107.
57. Needham, S.R.; Roberts, S.K.; Arkhipov, A.; Mysore, V.P.; Tynan, C.J.; Zanetti-Domingues, L.C.; Kim, E.T.; Losasso, V.; Korovesis, D.; Hirsch, M.; et al. EGFR oligomerization organizes kinase-active dimers into competent signalling platforms. Nat. Commun. 2016, 7, 13307.
58. Ferguson, K.M.; Berger, M.B.; Mendrola, J.M.; Cho, H.S.; Leahy, D.J.; Lemmon, M.A. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Moll. Cell 2003, 11, 507-517.
59. Ferguson, K.M. Structure-based view of epidermal growth factor receptor regulation. Annu. Rev. Biophys. 2008, 37, 353-373.
60. Cho, H.S.; Leahy, D.J. Structure of the extracellular region of HER3 reveals an interdomain tether. Science 2002, 297, 1330-1333.
61. Bouyain, S.; Longo, P.A.; Li, S.; Ferguson, K.M.; Leahy, D.J. The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand. Proc. Natl. Acad. Sci. USA 2005, 102, 15024-15029.
62. Berezov, A.; Chen, J.; Liu, Q.; Zhang, H.T.; Greene, M.I.; Murali, R. Disabling receptor ensembles with rationally designed interface peptidomimetics. J. Biol. Chem. 2002, 277, 28330-28339.
63. Jura, N.; Endres, N.F.; Engel, K.; Deindl, S.; Das, R.; Lamers, M.H.; Wemmer, D.E.; Zhang, X.; Kuriyan, J. Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell 2009, 137, 1293-1307.
64. Zhang, X.; Gureasko, J.; Shen, K.; Cole, P.A.; Kuriyan, J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006, 125, 1137-1149.
65. Sorkin, A.; Mazzotti, M.; Sorkina, T.; Scotto, L.; Beguinot, L. Epidermal growth factor receptor interaction with clathrin adaptors is mediated by the Tyr974-containing internalization motif. J. Biol. Chem. 1996, 271, 13377-13384.
66. Red Brewer, M.; Choi, S.H.; Alvarado, D.; Moravcevic, K.; Pozzi, A.; Lemmon, M.A.; Carpenter, G. The juxtamembrane region of the EGF receptor functions as an activation domain. Mol. Cell 2009, 34, 641-651.
67. Huse, M.; Kuriyan, J. The conformational plasticity of protein kinases. Cell 2002, 109, 275-282.
68. Schlessinger, J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 2002, 110, 669-672.
69. Schlessinger, J. Allosteric regulation of the epidermal growth factor receptor kinase. J. Cell Biol. 1986, 103, 2067-2072.
70. Macdonald, J.L.; Pike, L.J. Heterogeneity in EGF-binding affinities arises from negative cooperativity in an aggregating system. Proc. Natl. Acad. Sci. USA 2008, 105, 112-117.
71. Macdonald-Obermann, J.L.; Pike, L.J. The intracellular juxtamembrane domain of the epidermal growth factor (EGF) receptor is responsible for the allosteric regulation of EGF binding. J. Biol. Chem. 2009, 284, 13570-13576.
72. Wofsy, C.; Goldstein, B.; Lund, K.; Wiley, H.S. Implications of epidermal growth factor (EGF) induced egf receptor aggregation. Biophys. J. 1992, 63, 98-110.
73. De Meyts, P.; Roth, J.; Neville, D.M., Jr.; Gavin, J.R., III; Lesniak, M.A. Insulin interactions with its receptors:Experimental evidence for negative cooperativity. Biochem. Biophys. Res. Commun. 1973, 55, 154-161.
74. Alvarado, D.; Klein, D.E.; Lemmon, M.A. Structural basis for negative cooperativity in growth factor binding to an EGF receptor. Cell 2010, 142, 568-579.
75. Liu, P.; Cleveland, T.E., 4th; Bouyain, S.; Byrne, P.O.; Longo, P.A.; Leahy, D.J. A single ligand is sufficient to activate EGFR dimers. Proc. Natl. Acad. Sci. USA 2012, 109, 10861-10866.
76. Adak, S.; DeAndrade, D.; Pike, L.J. The tethering arm of the EGF receptor is required for negative cooperativity and signal transduction. J. Biol. Chem. 2011, 286, 1545-1555.
77. Adak, S.; Yang, K.S.; Macdonald-Obermann, J.; Pike, L.J. The membrane-proximal intracellular domain of the epidermal growth factor receptor underlies negative cooperativity in ligand binding. J. Biol. Chem. 2011, 286, 45146-45155.
78. Shoyab, M.; De Larco, J.E.; Todaro, G.J. Biologically active phorbol esters specifically alter affinity of epidermal growth factor membrane receptors. Nature 1979, 279, 387-391.
79. Magun, B.E.; Matrisian, L.M.; Bowden, G.T. Epidermal growth factor. Ability of tumor promoter to alter its degradation, receptor affinity and receptor number. J. Biol. Chem. 1980, 255, 6373-6381.
80. Hunter, T.; Ling, N.; Cooper, J.A. Protein kinase C phosphorylation of the EGF receptor at a threonine residue close to the cytoplasmic face of the plasma membrane. Nature 1984, 311, 480-483.
81. Downward, J.; Waterfield, M.D.; Parker, P.J. Autophosphorylation and protein kinase C phosphorylation of the epidermal growth factor receptor. Effect on tyrosine kinase activity and ligand binding affinity. J. Biol. Chem. 1985, 260, 14538-14546.
82. Thiel, K.W.; Carpenter, G. Epidermal growth factor receptor juxtamembrane region regulates allosteric tyrosine kinase activation. Proc. Natl. Acad. Sci. USA 2007, 104, 19238-19243.
83. Chen, L.; Merzlyakov, M.; Cohen, T.; Shai, Y.; Hristova, K. Energetics of ErbB1 transmembrane domain dimerization in lipid bilayers. Biophys. J. 2009, 96, 4622-4630.
84. Bocharov, E.V.; Mineev, K.S.; Pavlov, K.V.; Akimov, S.A.; Kuznetsov, A.S.; Efremov, R.G.; Arseniev, A.S. Helix-helix interactions in membrane domains of bitopic proteins: Specificity and role of lipid environment. Biochim. Biophys. Acta 2017, 1859, 561-576.
85. Bocharov, E.V.; Sharonov, G.V.; Bocharova, O.V.; Pavlov, K.V. Conformational transitions and interactions underlying the function of membrane embedded receptor protein kinases. Biochim. Biophys. Acta 2017, doi:10.1016/j.bbamem.2017.01.025.
86. Maruyama, I.N. Receptor Guanylyl Cyclases in Sensory Processing. Front. Endocrinol. 2017, 7, 173.
87. Bocharov, E.V.; Lesovoy, D.M.; Pavlov, K.V.; Pustovalova, Y.E.; Bocharova, O.V.; Arseniev, A.S. Alternative packing of EGFR transmembrane domain suggests that protein-lipid interactions underlie signal conduction across membrane. Biochim. Biophys. Acta 2016, 1858, 1254-1261.
88. Clayton, A.H.; Orchard, S.G.; Nice, E.C.; Posner, R.G.; Burgess, A.W. Predominance of activated EGFR higher-order oligomers on the cell surface. Growth Factors 2008, 26, 316-324.
89. Kozer, N.; Barua, D.; Henderson, C.; Nice, E.C.; Burgess, A.W.; Hlavacek, W.S.; Clayton, A.H. Recruitment of the adaptor protein Grb2 to EGFR tetramers. Biochemistry 2014, 53, 2594-2604.
90. Curran, T.G.; Zhang, Y.; Ma, D.J.; Sarkaria, J.N.; White, F.M. MARQUIS: A multiplex method for absolute quantification of peptides and posttranslational modifications. Nat. Commun. 2015, 6, 5924.
91. Wilson, K.J.; Mill, C.; Lambert, S.; Buchman, J.; Wilson, T.R.; Hernandez-Gordillo, V.; Gallo, R.M.; Ades, L.M.; Settleman, J.; Riese, D.J., 2nd. EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling. Growth Factors 2012, 30, 107-116.
92. Saito, T.; Okada, S.; Ohshima, K.; Yamada, E.; Sato, M.; Uehara, Y.; Shimizu, H.; Pessin, J.E.; Mori, M. Differential activation of epidermal growth factor (EGF) receptor downstream signaling pathways by betacellulin and EGF. Endocrinology 2004, 145, 4232-4243.
93. Macdonald-Obermann, J.L.; Pike, L.J. Different epidermal growth factor (EGF) receptor ligands show distinct kinetics and biased or partial agonism for homodimer and heterodimer formation. J. Biol. Chem. 2014, 289, 26178-26188.
94. Roepstorff, K.; Grandal, M.V.; Henriksen, L.; Knudsen, S.L.; Lerdrup, M.; Grovdal, L.; Willumsen, B.M.; van Deurs, B. Differential effects of EGFR ligands on endocytic sorting of the receptor. Traffic 2009, 10, 1115-1127.
95. Prenzel, N.; Fischer, O.M.; Streit, S.; Hart, S.; Ullrich, A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr. Relat. Cancer 2001, 8, 11-31.
96. Zandi, R.; Larsen, A.B.; Andersen, P.; Stockhausen, M.T.; Poulsen, H.S. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal. 2007, 19, 2013-2023.
97. Pedersen, M.W.; Tkach, V.; Pedersen, N.; Berezin, V.; Poulsen, H.S. Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility. Int. J. Cancer 2004, 108, 643-653.
98. Pedersen, M.W.; Pedersen, N.; Damstrup, L.; Villingshoj, M.; Sonder, S.U.; Rieneck, K.; Bovin, L.F.; Spang-Thomsen, M.; Poulsen, H.S. Analysis of the epidermal growth factor receptor specific transcriptome: Effect of receptor expression level and an activating mutation. J. Cell. Biochem. 2005, 96, 412-427.
99. Nicholson, R.I.; Gee, J.M.; Harper, M.E. EGFR and cancer prognosis. Eur. J. Cancer 2001, 37, S9-S15.
100. Bhargava, R.; Gerald, W.L.; Li, A.R.; Pan, Q.; Lal, P.; Ladanyi, M.; Chen, B. EGFR gene amplification in breast cancer: Correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod. Pathol. 2005, 18, 1027-1033.
101. Suzuki, S.; Dobashi, Y.; Sakurai, H.; Nishikawa, K.; Hanawa, M.; Ooi, A. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study. Cancer 2005, 103, 1265-1273.
102. Wong, A.J.; Bigner, S.H.; Bigner, D.D.; Kinzler, K.W.; Hamilton, S.R.; Vogelstein, B. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc. Natl. Acad. Sci. USA 1987, 84, 6899-6903.
103. Furgason, J.M.; Li, W.; Milholland, B.; Cross, E.; Li, Y.; McPherson, C.M.; Warnick, R.E.; Rixe, O.; Stambrook, P.J.; Vijg, J.; et al. Whole genome sequencing of glioblastoma multiforme identifies multiple structural variations involved in EGFR activation. Mutagenesis 2014, 29, 341-350.
104. Sheikh, M.S.; Carrier, F.; Johnson, A.C.; Ogdon, S.E.; Fornace, A.J., Jr. Identification of an additional p53- responsive site in the human epidermal growth factor receptor gene promotor. Oncogene 1997, 15, 1095-1101.
105. Ludes-Meyers, J.H.; Subler, M.A.; Shivakumar, C.V.; Munoz, R.M.; Jiang, P.; Bigger, J.E.; Brown, D.R.; Deb, S.P.; Deb, S. Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. Mol. Cell. Biol. 1996, 16, 6009-6019.
106. McInerney, J.M.; Wilson, M.A.; Strand, K.J.; Chrysogelos, S.A. A strong intronic enhancer element of the EGFR gene is preferentially active in high EGFR expressing breast cancer cells. J. Cell. Biochem. 2001, 80, 538-549.
107. Chrysogelos, S.A. Chromatin structure of the EGFR gene suggests a role for intron 1 sequences in its regulation in breast cancer cells. Nucleic Acids Res. 1993, 21, 5736-5741.
108. Gebhardt, F.; Zanker, K.S.; Brandt, B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J. Biol. Chem. 1999, 274, 13176-13180.
109. Buerger, H.; Packeisen, J.; Boecker, A.; Tidow, N.; Kersting, C.; Bielawski, K.; Isola, J.; Yatabe, Y.; Nakachi, K.; Boecker, W.; et al. Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence-First results of an inter-ethnic breast cancer study. J. Pathol. 2004, 203, 545-550.
110. Amador, M.L.; Oppenheimer, D.; Perea, S.; Maitra, A.; Cusatis, G.; Iacobuzio-Donahue, C.; Baker, S.D.; Ashfaq, R.; Takimoto, C.; Forastiere, A.; et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res. 2004, 64, 9139-9143.
111. Johnston, D.; Hall, H.; DiLorenzo, T.P.; Steinberg, B.M. Elevation of the epidermal growth factor receptor and dependent signaling in human papillomavirus-infected laryngeal papillomas. Cancer Res. 1999, 59, 968-974.
112. Wong, A.J.; Ruppert, J.M.; Bigner, S.H.; Grzeschik, C.H.; Humphrey, P.A.; Bigner, D.S.; Vogelstein, B. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc. Natl. Acad. Sci. USA 1992, 89, 2965-2969.
113. Frederick, L.; Wang, X.Y.; Eley, G.; James, C.D. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 2000, 60, 1383-1387.
114. Humphrey, P.A.; Gangarosa, L.M.; Wong, A.J.; Archer, G.E.; Lund-Johansen, M.; Bjerkvig, R.; Laerum, O.D.; Friedman, H.S.; Bigner, D.D. Deletion-mutant epidermal growth factor receptor in human gliomas:Effects of type II mutation on receptor function. Biochem. Biophys. Res. Commun. 1991, 178, 1413-1420.
115. Francis, J.M.; Zhang, C.Z.; Maire, C.L.; Jung, J.; Manzo, V.E.; Adalsteinsson, V.A.; Homer, H.; Haidar, S.; Blumenstiel, B.; Pedamallu, C.S.; et al. EGFR variant heterogeneity in glioblastoma resolved through singlenucleus sequencing. Cancer Discov. 2014, 4, 956-971.
116. Nagane, M.; Coufal, F.; Lin, H.; Bogler, O.; Cavenee, W.K.; Huang, H.J. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res. 1996, 56, 5079-5086.
117. Antonyak, M.A.; Moscatello, D.K.; Wong, A.J. Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor. J. Biol. Chem. 1998, 273, 2817-2822.
118. Chu, C.T.; Everiss, K.D.; Wikstrand, C.J.; Batra, S.K.; Kung, H.J.; Bigner, D.D. Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem. J. 1997, 324, 855-861.
119. Grandal, M.V.; Zandi, R.; Pedersen, M.W.; Willumsen, B.M.; van Deurs, B.; Poulsen, H.S. EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes. Carcinogenesis 2007, 28, 1408-1417.
120. Huang, H.S.; Nagane, M.; Klingbeil, C.K.; Lin, H.; Nishikawa, R.; Ji, X.D.; Huang, C.M.; Gill, G.N.; Wiley, H.S.; Cavenee, W.K. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J. Biol. Chem. 1997, 272, 2927-2935.
121. Greenall, S.A.; Donoghue, J.F.; Gottardo, N.G.; Johns, T.G.; Adams, T.E. Glioma-specific Domain IV EGFR cysteine mutations promote ligand-induced covalent receptor dimerization and display enhanced sensitivity to dacomitinib in vivo. Oncogene 2015, 34, 1658-1666.
122. Lee, J.C.; Vivanco, I.; Beroukhim, R.; Huang, J.H.Y.; Feng, W.L.; DeBiasi, R.M.; Yoshimoto, K.; King, J.C.; Nghiemphu, P.; Yuza, Y.; et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 2006, 3, e485.
123. Arjona, D.; Bello, M.J.; Alonso, M.E.; Aminoso, C.; Isla, A.; De Campos, J.M.; Sarasa, J.L.; Gutierrez, M.; Villalobo, A.; Rey, J.A. Molecular analysis of the EGFR gene in astrocytic gliomas: mRNA expression, quantitative-PCR analysis of non-homogeneous gene amplification and DNA sequence alterations. Neuropathol. Appl. Neurobiol. 2005, 31, 384-394.
124. Idbaih, A.; Aimard, J.; Boisselier, B.; Marie, Y.; Paris, S.; Criniere, E.; Carvalho Silva, R.; Laigle-Donadey, F.; Rousseau, A.; Mokhtari, K.; et al. Epidermal growth factor receptor extracellular domain mutations in primary glioblastoma. Neuropathol. Appl. Neurobiol. 2009, 35, 208-213.
125. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455, 1061-1068.
126. Parsons, D.W.; Jones, S.; Zhang, X.; Lin, J.C.; Leary, R.J.; Angenendt, P.; Mankoo, P.; Carter, H.; Siu, I.M.; Gallia, G.L.; et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321, 1807-1812.
127. Greulich, H.; Chen, T.H.; Feng, W.; Janne, P.A.; Alvarez, J.V.; Zappaterra, M.; Bulmer, S.E.; Frank, D.A.; Hahn, W.C.; Sellers, W.R.; et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005, 2, e313.
128. Choi, S.H.; Mendrola, J.M.; Lemmon, M.A. EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer. Oncogene 2007, 26, 1567-1576.
129. Jiang, J.; Greulich, H.; Jänne, P.A.; Sellers, W.R.; Meyerson, M.; Griffin, J.D. Epidermal growth factor-Independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces Gefitinib-sensitive cell cycle progression. Cancer Research 2005, 65, 8968-8974.
130. Yun, C.H.; Boggon, T.J.; Li, Y.; Woo, M.S.; Greulich, H.; Meyerson, M.; Eck, M.J. Structures of lung cancerderived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007, 11, 217-227.
131. Shigematsu, H.; Gazdar, A.F. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int. J. Cancer 2006, 118, 257-262.
132. Chan, S.K.; Gullick, W.J.; Hill, M.E. Mutations of the epidermal growth factor receptor in non-small cell lung cancer-Search and destroy. Eur. J. Cancer 2006, 42, 17-23.
133. Paez, J.G.; Janne, P.A.; Lee, J.C., Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F.J.; Lindeman, N.; Boggon, T.J.; et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497-1500.
134. Gilmer, T.M.; Cable, L.; Alligood, K.; Rusnak, D.; Spehar, G.; Gallagher, K.T.; Woldu, E.; Carter, H.L.; Truesdale, A.T.; Shewchuk, L.; et al. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib. Cancer Res. 2008, 68, 571-579.
135. Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Haserlat, S.M.; Supko, J.G.; Haluska, F.G.; et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350, 2129-2139.
136. Chou, T.Y.; Chiu, C.H.; Li, L.H.; Hsiao, C.Y.; Tzen, C.Y.; Chang, K.T.; Chen, Y.M.; Perng, R.P.; Tsai, S.F.; Tsai, C.M. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin. Cancer Res. 2005, 11, 3750-3757.
137. Van Noesel, J.; van der Ven, W.H.; van Os, T.A.; Kunst, P.W.; Weegenaar, J.; Reinten, R.J.; Kancha, R.K.; Duyster, J.; van Noesel, C.J. Activating germline R776H mutation in the epidermal growth factor receptor associated with lung cancer with squamous differentiation. J. Clin. Oncol. 2013, 31, e161-e164.
138. Ruan, Z.; Kannan, N. Mechanistic insights into R776H mediated activation of epidermal growth factor receptor kinase. Biochemistry 2015, 54, 4216-4225.
139. Shan, Y.; Eastwood, M.P.; Zhang, X.; Kim, E.T.; Arkhipov, A.; Dror, R.O.; Jumper, J.; Kuriyan, J.; Shaw, D.E. Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization. Cell 2012, 149, 860-870.
140. Red Brewer, M.; Yun, C.H.; Lai, D.; Lemmon, M.A.; Eck, M.J.; Pao, W. Mechanism for activation of mutated epidermal growth factor receptors in lung cancer. Proc. Natl. Acad. Sci. USA 2013, 110, E3595-3604.
141. Cai, C.Q.; Peng, Y.; Buckley, M.T.; Wei, J.; Chen, F.; Liebes, L.; Gerald, W.L.; Pincus, M.R.; Osman, I.; Lee, P. Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations. Oncogene 2008, 27, 3201-3210.
142. Murugan, A.K.; Dong, J.; Xie, J.; Xing, M. Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 mutations in thyroid cancers. Endocr. Pathol. 2011, 22, 97-102.
143. Schwentner, I.; Witsch-Baumgartner, M.; Sprinzl, G.M.; Krugmann, J.; Tzankov, A.; Jank, S.; Zwierzina, H.; Loeffler-Ragg, J. Identification of the rare EGFR mutation p.G796S as somatic and germline mutation in white patients with squamous cell carcinoma of the head and neck. Head Neck 2008, 30, 1040-1044.
144. Sharma, S.V.; Bell, D.W.; Settleman, J.; Haber, D.A. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 2007, 7, 169-181.
145. Cho, J.; Chen, L.; Sangji, N.; Okabe, T.; Yonesaka, K.; Francis, J.M.; Flavin, R.J.; Johnson, W.; Kwon, J.; Yu, S.; et al. Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. Cancer Res. 2013, 73, 6770-6779.
146. Wood, E.R.; Truesdale, A.T.; McDonald, O.B.; Yuan, D.; Hassell, A.; Dickerson, S.H.; Ellis, B.; Pennisi, C.; Horne, E.; Lackey, K.; et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004, 64, 6652-6659.
147. Fenstermaker, R.A.; Ciesielski, M.J.; Castiglia, G.J. Tandem duplication of the epidermal growth factor receptor tyrosine kinase and calcium internalization domains in A-172 glioma cells. Oncogene 1998, 16, 3435-3443.
148. Ozer, B.H.; Wiepz, G.J.; Bertics, P.J. Activity and cellular localization of an oncogenic glioblastoma multiforme-associated EGF receptor mutant possessing a duplicated kinase domain. Oncogene 2010, 29, 855-864.
149. Gallant, J.N.; Sheehan, J.H.; Shaver, T.M.; Bailey, M.; Lipson, D.; Chandramohan, R.; Red Brewer, M.; York, S.J.; Kris, M.G.; Pietenpol, J.A.; et al. EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. Cancer Discov. 2015, 5, 1155-1163.
150. Jeuken, J.; Sijben, A.; Alenda, C.; Rijntjes, J.; Dekkers, M.; Boots-Sprenger, S.; McLendon, R.; Wesseling, P. Robust detection of EGFR copy number changes and EGFR variant III: Technical aspects and relevance for glioma diagnostics. Brain Pathol. 2009, 19, 661-671.
151. Ekstrand, A.J.; Sugawa, N.; James, C.D.; Collins, V.P. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc. Natl. Acad. Sci. USA 1992, 89, 4309-4313.
152. Kuan, C.T.; Wikstrand, C.J.; Bigner, D.D. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr. Relat. Cancer 2001, 8, 83-96.
153. Pines, G.; Huang, P.H.; Zwang, Y.; White, F.M.; Yarden, Y. EGFRvIV: A previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism. Oncogene 2010, 29, 5850-5860.
154. Brennan, C.W.; Verhaak, R.G.; McKenna, A.; Campos, B.; Noushmehr, H.; Salama, S.R.; Zheng, S.; Chakravarty, D.; Sanborn, J.Z.; Berman, S.H.; et al. The somatic genomic landscape of glioblastoma. Cell 2013, 155, 462-477.
155. Cho, J.; Pastorino, S.; Zeng, Q.; Xu, X.; Johnson, W.; Vandenberg, S.; Verhaak, R.; Cherniack, A.D.; Watanabe, H.; Dutt, A.; et al. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. Cancer Res. 2011, 71, 7587-7596.
156. Imielinski, M.; Berger, A.H.; Hammerman, P.S.; Hernandez, B.; Pugh, T.J.; Hodis, E.; Cho, J.; Suh, J.; Capelletti, M.; Sivachenko, A.; et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012, 150, 1107-1120.
157. Park, A.K.; Francis, J.M.; Park, W.Y.; Park, J.O.; Cho, J. Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants. Oncotarget 2015, 6, 8839-8850.